Patents by Inventor Yoshimasa Sakamoto
Yoshimasa Sakamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120213799Abstract: The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.Type: ApplicationFiled: October 28, 2010Publication date: August 23, 2012Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Miyuki Nishimura, Yoshimasa Sakamoto, Tetsu Kawano, Toshio Imai
-
Patent number: 8232052Abstract: In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.Type: GrantFiled: August 25, 2010Date of Patent: July 31, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Yoshimasa Sakamoto
-
Publication number: 20120148592Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: ApplicationFiled: November 18, 2011Publication date: June 14, 2012Inventors: Toshio Imai, Brad Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 8198081Abstract: An object of the present invention is to provide a probe, a primer, a primer set and an antibody for use in the detection or selection of a dopaminergic neuron progenitor cell. The present invention provides a probe, a primer and a primer set for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron proliferative progenitor cell, which can hybridize with a nucleotide sequence of a 187A5 gene, or a complementary sequence thereto, and an antibody for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron progenitor cell, which is capable of binding to a 187A5 protein.Type: GrantFiled: April 11, 2007Date of Patent: June 12, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yoshimasa Sakamoto
-
Publication number: 20120021417Abstract: The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.Type: ApplicationFiled: September 29, 2011Publication date: January 26, 2012Applicant: EISAI R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani, Yoshimasa Sakamoto
-
Patent number: 8067161Abstract: The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.Type: GrantFiled: August 18, 2006Date of Patent: November 29, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani, Yoshimasa Sakamoto
-
Patent number: 8039224Abstract: A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.Type: GrantFiled: October 8, 2009Date of Patent: October 18, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Yasuko Nakagawa, Yuichi Ono, Yoshimasa Sakamoto, Eri Mizuhara, Tomoya Nakatani, Yoshimi Takai
-
Publication number: 20110229889Abstract: The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of an Msx1 gene or an Msx2 gene, or a complementary sequence thereto, and an antibody against an Msx1 protein or an Msx2 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.Type: ApplicationFiled: March 24, 2011Publication date: September 22, 2011Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani, Yoshimasa Sakamoto
-
Publication number: 20110008769Abstract: An object of the present invention is to provide a probe, a primer, a primer set and an antibody for use in the detection or selection of a dopaminergic neuron progenitor cell. The present invention provides a probe, a primer and a primer set for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron proliferative progenitor cell, which can hybridize with a nucleotide sequence of a 187A5 gene, or a complementary sequence thereto, and an antibody for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron progenitor cell, which is capable of binding to a 187A5 protein.Type: ApplicationFiled: April 11, 2007Publication date: January 13, 2011Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yuchi Ono, Yoshimasa Sakamoto
-
Publication number: 20100323366Abstract: In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.Type: ApplicationFiled: August 25, 2010Publication date: December 23, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Yoshimasa Sakamoto
-
Patent number: 7807371Abstract: In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.Type: GrantFiled: April 25, 2008Date of Patent: October 5, 2010Assignee: Eisai R & D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Yoshimasa Sakamoto
-
Publication number: 20100216164Abstract: The present invention provides the mPrickle gene which encodes a protein present in mammalian PSD fractions. The mPrickle protein is localized in synapses, and binds to the scaffold protein PSD-95. Precipitation of endogenous mPrickle using an anti-mPrickle antibody results in the coprecipitation of NMDA receptors, and thus, mPrickle can be used in drug delivery systems that target NMDA receptors. NMDA receptors are closely related to learning and memory, and are also suggested to be involved in mental disorders. Thus, in the future, mPrickle is expected to be applicable to the diagnosis and/or treatment of neurodegenerative diseases associated with learning/memory, such as mental deterioration and dementia.Type: ApplicationFiled: February 24, 2009Publication date: August 26, 2010Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Masakazu Takeuchi, Keiko Sato, Yoshimasa Sakamoto, Maki Tawarada, Toshihisa Ohtsuka
-
Publication number: 20100203505Abstract: The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of an Msx1 gene or an Msx2 gene, or a complementary sequence thereto, and an antibody against an Msx1 protein or an Msx2 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.Type: ApplicationFiled: August 18, 2006Publication date: August 12, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani, Yoshimasa Sakamoto
-
Publication number: 20100203570Abstract: A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.Type: ApplicationFiled: October 8, 2009Publication date: August 12, 2010Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yasuko Nakagawa, Yuichi Ono, Yoshimasa Sakamoto, Eri Mizuhara, Tomoya Nakatani, Yoshimi Takai
-
Publication number: 20100028866Abstract: The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.Type: ApplicationFiled: August 18, 2006Publication date: February 4, 2010Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yuichi Ono, Yasuko Nakagawa, Tomoya Nakatani, Yoshimasa Sakamoto
-
Patent number: 7622270Abstract: A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.Type: GrantFiled: October 21, 2003Date of Patent: November 24, 2009Assignee: Eisai R&D Management Co., Ltd.Inventors: Yasuko Nakagawa, Yuichi Ono, Yoshimasa Sakamoto, Eri Mizuhara, Tomoya Nakatani, Yoshimi Takai
-
Publication number: 20080280301Abstract: In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.Type: ApplicationFiled: April 25, 2008Publication date: November 13, 2008Applicant: Eisai R&D Management Co, Ltd.Inventors: Yuichi Ono, Yasuko Nakagawa, Yoshimasa Sakamoto
-
Publication number: 20080199437Abstract: The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.Type: ApplicationFiled: July 22, 2005Publication date: August 21, 2008Applicant: EISAI CO., LTD.Inventors: Yoshimasa Sakamoto, Yuichi Ono, Toshio Imai, Yasuko Nakagawa
-
Publication number: 20070122882Abstract: A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.Type: ApplicationFiled: January 11, 2007Publication date: May 31, 2007Applicant: Eisai Co., Ltd.Inventors: Yasuko Nakagawa, Yuichi Ono, Yoshimasa Sakamoto, Eri Mizuhara, Tomoya Nakatani, Yoshimi Takai
-
Publication number: 20060292669Abstract: The present invention provides the mPrickle gene which encodes a protein present in mammalian PSD fractions. The mPrickle protein is localized in synapses, and binds to the scaffold protein PSD-95. Precipitation of endogenous mPrickle using an anti-mPrickle antibody results in the coprecipitation of NMDA receptors, and thus, mPrickle can be used in drug delivery systems that target NMDA receptors. NMDA receptors are closely related to learning and memory, and are also suggested to be involved in mental disorders. Thus, in the future, mPrickle is expected to be applicable to the diagnosis and/or treatment of neurodegenerative diseases associated with learning/memory, such as mental deterioration and dementia.Type: ApplicationFiled: November 28, 2003Publication date: December 28, 2006Applicant: Eisai Co., Ltd.Inventors: Masakazu Takeuchi, Keiko Sato, Yoshimasa Sakamoto, Maki Tawarada, Toshihisa Ohtsuka